KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Non-Current Assets: 2009-2025

Historic Non-Current Assets for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $254.3 million.

  • Acadia Pharmaceuticals' Non-Current Assets rose 34.87% to $254.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $254.3 million, marking a year-over-year increase of 34.87%. This contributed to the annual value of $249.4 million for FY2024, which is 87.79% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Non-Current Assets of $254.3 million as of Q3 2025, which was down 4.02% from $265.0 million recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Non-Current Assets peaked at $265.0 million during Q2 2025, and registered a low of $76.8 million during Q3 2021.
  • Over the past 3 years, Acadia Pharmaceuticals' median Non-Current Assets value was $185.2 million (recorded in 2024), while the average stood at $195.7 million.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Non-Current Assets surged by 252.55% in 2021 and then fell by 2.95% in 2022.
  • Quarterly analysis of 5 years shows Acadia Pharmaceuticals' Non-Current Assets stood at $82.3 million in 2021, then decreased by 2.95% to $79.9 million in 2022, then spiked by 66.30% to $132.8 million in 2023, then surged by 87.79% to $249.4 million in 2024, then spiked by 34.87% to $254.3 million in 2025.
  • Its last three reported values are $254.3 million in Q3 2025, $265.0 million for Q2 2025, and $261.4 million during Q1 2025.